en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
News
2026
2025
2024
2023
2022
2021
2020
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jun 3, 2020
2020
News
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
News
Read more
Apr 23, 2020
2020
Press Release Non-regulatory
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Non-regulatory Press Release
Read more
Apr 2, 2020
2020
News
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
News
Read more
Jan 10, 2020
2020
News
Funding from the Sjöberg Foundation
News
Read more
Nov 13, 2019
2019
News
Funding by the Swedish Cancer Society
News
Read more
Mar 2, 2018
2018
News
Status update by Uppsala University on the clinical phase I/II-study in NET
News
Read more
Dec 12, 2016
2016
News
Swedish Public Radio interviews Professor Magnus Essand
News
Read more
Dec 12, 2016
2016
News
The Medical Journal writes about a clinical study
News
Read more
Oct 27, 2014
2014
News
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
News
Read more
Jun 15, 2013
2013
News
Successful crowdfunding
News
Read more
Previous
8 / 8
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept